Aldesleukin Completed Phase 3 Trials for Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Basophilic Leukemia / Childhood Acute Monocytic Leukemia (M5b) / Adult Acute Monoblastic Leukemia (M5a) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Erythroleukemia (M6a) / Untreated Adult Acute Myeloid Leukemia / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Pure Erythroid Leukemia (M6b) / Childhood Acute Basophilic Leukemia / Adult Acute Myeloid Leukemia With Del(5q) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / De Novo Myelodysplastic Syndromes / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Erythroleukemia (M6) / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Eosinophilic Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5) / Childhood Acute Eosinophilic Leukemia / Adult Acute Erythroid Leukemia (M6) / Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5) / Childhood Myelodysplastic Syndromes Treatment

IndicationsStatusPurposePhase
CompletedTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00006363Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia